A MULTICENTER, RANDOMIZED, PARTICIPANT- AND INVESTIGATOR -BLINDED, PLACEBO-CONTROLLED, PHASE 2A STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF GIA632 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
- Registry ID
- CGIA632A12201
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- NOVARTIS PHARMACEUTICALS CANADA INC
- Start date
- 2026-04-24
- Last update
- 2025-10-24
Conditions
Related clinical trials
- A PHASE 2B, MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAMOTESKIMAB IN ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
- A PHASE 2B, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF JNJ-95597528 FOR THE TREATMENT OF ADULT PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
- A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF GALVOKIMIG IN ADULT STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
- A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, DOSE-RANGING STUDY WITH AN OPEN-LABEL PERIOD INVESTIGATING THE EFFICACY AND SAFETY PROFILE OF KT-621 ADMINISTERED ORALLY TO PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS.
- AN EXTENSION STUDY TO EVALUATE THE LONG- TERM SAFETY AND EFFICACY OF AFIMKIBART (RO7790121) IN PATIENTS WITH ATOPIC DERMATITIS WHO PARTICIPATED IN PREVIOUS AFIMKIBART CLINICAL TRIALS
- A PHASE 2A, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO
EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF MULTIPLE SUBCUTANEOUS
DOSES OF TRIV-509 IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
View on source registry